Xavier Becerra, HHS Secretary (Greg Nash/Pool via AP Images)
September 23, 2021 11:24 AM EDT
Pharma

HHS lines up No­var­tis, Lil­ly, As­traZeneca and 3 oth­er drug­mak­ers for fines due to drug dis­count vi­o­la­tions

Zachary Brennan

Senior Editor

As drug­mak­ers con­tin­ue to bat­tle Pres­i­dent Biden’s HHS in court over al­leged 340B drug dis­count vi­o­la­tions, HHS sent let­ters on Wednes­day to six com­pa­nies in­form­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times